Bloating and Fatigue: Why Killing Gut Organisms Backfires

Bloating and fatigue are the two symptoms most likely to end with an organism blamed for them. A panel arrives with a name highlighted, a protocol follows, and a year or two later the symptoms are unchanged while the flora is thinner than it started. The organisms on those reports live in most people who feel perfectly well. What the protocol changed was the room they live in.

Watch The Wrong Enemy on Your Stool Report for the ten-minute version of this argument, drawn from The Angry Gut, by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Ami Michelle Grimes. Below is what an interventional pain practice does with it, because a depleted gut does not stay a digestive problem for long.

A species list is a photograph, not a job record

A taxonomic panel names who is present. It cannot report what anyone is doing. The first brain reshuffles its population meal by meal, driven by vagal traffic and by whatever arrives in the nutrient stream, so a list of names tells you who showed up on one morning. Work shows up elsewhere: in metabolites, in the immune response provoked, and in fermentation gases on a breath test. An international consensus panel of sixty-nine specialists reviewed the direct-to-consumer versions of these panels and found no proven value for them in clinical practice.

Bloating and fatigue, and the organisms most people already carry

Start with the yeast, because it sells the most protocols. In a healthy cohort from the Human Microbiome Project, Candida albicans turned up in 80.8% of stool samples, and baker’s yeast in 96.8%. A positive result describes the species. It does not diagnose the person.

I wrote antifungals for reports like that for years, because that is what I was taught a highlighted line meant. The trial that changed my mind was the only one of its kind. When nystatin was tested, randomized and double-blind, against placebo for the symptom cluster patients now bring me, whole-body symptom scores improved 25% on the active regimens and 23% on placebo alone. The drug cleared the vaginal symptoms it is actually indicated for and did nothing else. That is what a real indication looks like.

The protozoan runs stranger. Among 296 healthy Malian children, the ones colonized with Blastocystis carried significantly higher bacterial richness and diversity than the ones without it. Where yeast genuinely turns dangerous, the sequence runs opposite to the folklore: among transplant patients, six of eight who developed a bloodstream fungal infection first showed a single Candida species above 50% of their gut fungi, after a heavy loss of bacteria. The fungus does not empty the room. It moves in once the room is empty.

Why a thinned gut matters to a sensitized nervous system

This is what makes it a pain problem. Butyrate-producing bacteria push the cells lining the colon to burn oxygen, which keeps that surface airless. Deplete the producers and oxygen and nitrate leak into the lumen, and the organisms that expand are the ones equipped to breathe them. That chain was mapped in mice, so read it as mechanism.

The human end of it is a mortality cohort. Across 7,211 Finnish adults followed up to 15 years, a diversity score was not significantly associated with dying, at a corrected P value of 0.17. Composition was. The abundance of Enterobacteriaceae carried a hazard ratio of 1.14, and the top quarter ran a 34% greater risk of death than the bottom quarter. Those are the organisms that fill a thinned room. In a patient whose nervous system already amplifies every inflammatory input, adding a self-renewing source of that input is not neutral. It is the same logic as treating insulin before treating the joint, and part of why a clean scan and severe pain are not a contradiction.

What one course costs, measured rather than asserted

A single ordinary antibiotic, given at random to healthy volunteers, cut fecal diversity for as long as 4 months with clindamycin and as long as 12 months with ciprofloxacin, and the butyrate producers took the heaviest losses. The functional damage was quieter and larger. A month after that clindamycin course, 512 predicted gene functions had shifted, 11% of all of them. Amoxicillin is the unsettling case: it left diversity statistically untouched and still moved 272 predicted functions up and 434 down. A census can look normal while the job list has been rewritten. These are predictions from sequence data in small groups, so take the direction rather than the size.

Recovery is partial. Twelve men given three last-resort agents for four days looked near baseline within 1.5 months, yet nine species every one of them carried beforehand were still undetectable in most of them at day 180. And the dose-response should trouble anyone counting courses: across 6,104,245 people, every extra course raised the rate of inflammatory bowel disease, with ratios running from 1.11 to 1.15 across the age bands.

The fair objection is that sick people get antibiotics, so some apparent drug effect is really the illness. When fetal exposure and later asthma were compared within families, a hazard ratio of 1.28 in the full cohort fell to 0.99 between siblings. Part of that story is family. The argument survives it, because the volunteers who lost their butyrate producers were healthy and the drug was the only thing that changed.

Antibiotics are not the only culprits either. Proton pump inhibitors, antidiabetics and antipsychotics also break colonization resistance, three of the most prescribed classes in medicine, none labeled as a gut drug. Read an ordinary pain patient’s medication list and count.

The antibiotic is a bridge, and the bridge is not the failure

If there is a real pathogen, the prescription gets written without hesitation. What fails is the plan on the far side, and crossing again and again because nothing was ever built there. The agents these patients usually meet do not earn what is claimed for them. In the two pivotal irritable bowel trials, rifaximin brought adequate relief to 40.7% against 31.7% on placebo, roughly one patient helped in eleven. For bacterial overgrowth, the pooled eradication rate is 59%, with no significant difference from placebo or active control across the randomized trials. Herbal alternatives are not gentler, only thinner on evidence.

Notice who those trials enrolled: irritable bowel without constipation, cleaned of everything else. That strips out the patient carrying a pain syndrome, a metabolic syndrome and a mood disorder at once, who is exactly the patient in my exam room. So the evidence tier here is mechanistic and practice-based, and I would rather name the tier than pretend a trial answered a question it excluded.

What we measure, and what the rebuild asks of you

We stop counting names and start measuring activity: hydrogen and methane on a breath test, an inflammatory marker, and an honest record of a week of food. Then the work is addition. Fermentable plant material most days feeds the producers that keep the colon surface airless, which is the physiological reason food outperforms a capsule here. Sleep belongs in the same prescription, because the first brain answers to vagal traffic and that traffic depends on how you live. The fuel that lining runs on comes from those same bacteria, and the next part of the series turns from addition to subtraction: what the first brain does when you stop feeding it.

For the full evidence, the companion Deep Dive lists every study named here with its complete numbers, what each one does not show, and the questions worth asking your physician.

Cultivate the good and the bad runs out of room. That costs real food, real sleep and the patience to stop buying the next war. Another protocol costs another year and a thinner room to fight from.

Frequently asked questions

Can candida overgrowth cause bloating and fatigue?

The symptoms are real. The test that names the yeast cannot explain them. Four out of five people in a healthy cohort carried Candida albicans in stool, and much of what a fungal panel reports is food from the past few days. When bloating and fatigue persist, the better question is what the whole community is doing and what else is feeding the inflammatory load. Normal test results are often exactly what a condition predicts.

Do antibiotics make chronic pain worse?

No single course has been shown to cause pain. What has been measured is the terrain. One ordinary course reduced fecal diversity for months and thinned the butyrate producers, and each additional course carried a higher rate of inflammatory bowel disease in a Danish population of millions. In a body already carrying a high inflammatory load, that is a cost worth counting before the next prescription. Inflamed tissue changes what a nervous system is reacting to.

Should I treat Blastocystis hominis if a stool test found it?

That decision belongs to the physician who knows your immune status, not to a panel. In healthy children, carriage came with richer flora than in the children without it. The honest limit sits in an Italian series, where it was found in 22.3% of immunocompromised patients against 6.8% of immunocompetent ones. In a well person, treating it can mean treating a marker of the thing you were building. Deciding when a test earns its place is its own subject.

How long does the gut take to recover after antibiotics?

Longer than the prescription, and not completely. In men given last-resort agents, the community looked close to baseline within six weeks or so, yet species every man carried beforehand were still missing in most of them half a year later. Densely sampled volunteers ended up stable and different from where they began. The census returns faster than the residents do. Repopulating a gut you had to empty is a separate piece of work.

Is a probiotic capsule the right move after a course of antibiotics?

Tested head to head against doing nothing, probiotics delayed the return of a person’s own community and left it incomplete, while that person’s own banked stool restored it within days. A capsule of a stranger’s organisms is not the same intervention as feeding your own. Do not start, stop or change anything prescribed on your own; work the sequence through with your physician. Pain-sensing nerves in the gut wall are part of this circuitry.

Sources

1. Nash, A. K., Auchtung, T. A., Wong, M. C., Smith, D. P., Gesell, J. R., Ross, M. C., Stewart, C. J., Metcalf, G. A., Muzny, D. M., Gibbs, R. A., Ajami, N. J., & Petrosino, J. F. (2017). The gut mycobiome of the Human Microbiome Project healthy cohort. Microbiome, 5(1), 153. https://doi.org/10.1186/s40168-017-0373-4
2. Dismukes, W. E., Wade, J. S., Lee, J. Y., Dockery, B. K., & Hain, J. D. (1990). A randomized, double-blind trial of nystatin therapy for the candidiasis hypersensitivity syndrome. The New England Journal of Medicine, 323(25), 1717-1723. https://doi.org/10.1056/NEJM199012203232501
3. Kodio, A., Coulibaly, D., Koné, A. K., Konaté, S., Doumbo, S., Guindo, A., Bittar, F., Gouriet, F., Raoult, D., Thera, M. A., & Ranque, S. (2019). Blastocystis colonization is associated with increased diversity and altered gut bacterial communities in healthy Malian children. Microorganisms, 7(12), 649. https://doi.org/10.3390/microorganisms7120649
4. Salosensaari, A., Laitinen, V., Havulinna, A. S., Meric, G., Cheng, S., Perola, M., Valsta, L., Alfthan, G., Inouye, M., Watrous, J. D., Long, T., Salido, R. A., Sanders, K., Brennan, C., Humphrey, G. C., Sanders, J. G., Jain, M., Jousilahti, P., Salomaa, V., … Niiranen, T. (2021). Taxonomic signatures of cause-specific mortality risk in human gut microbiome. Nature Communications, 12(1), 2671. https://doi.org/10.1038/s41467-021-22962-y
5. Zaura, E., Brandt, B. W., Teixeira de Mattos, M. J., Buijs, M. J., Caspers, M. P. M., Rashid, M.-U., Weintraub, A., Nord, C. E., Savell, A., Hu, Y., Coates, A. R., Hubank, M., Spratt, D. A., Wilson, M., Keijser, B. J. F., & Crielaard, W. (2015). Same exposure but two radically different responses to antibiotics: Resilience of the salivary microbiome versus long-term microbial shifts in feces. mBio, 6(6), e01693-15. https://doi.org/10.1128/mBio.01693-15
6. Palleja, A., Mikkelsen, K. H., Forslund, S. K., Kashani, A., Allin, K. H., Nielsen, T., Hansen, T. H., Liang, S., Feng, Q., Zhang, C., Pyl, P. T., Coelho, L. P., Yang, H., Wang, J., Typas, A., Nielsen, M. F., Nielsen, H. B., Bork, P., Wang, J., … Pedersen, O. (2018). Recovery of gut microbiota of healthy adults following antibiotic exposure. Nature Microbiology, 3(11), 1255-1265. https://doi.org/10.1038/s41564-018-0257-9
7. Faye, A. S., Allin, K. H., Iversen, A. T., Agrawal, M., Faith, J., Colombel, J.-F., & Jess, T. (2023). Antibiotic use as a risk factor for inflammatory bowel disease across the ages: A population-based cohort study. Gut, 72(4), 663-670. https://doi.org/10.1136/gutjnl-2022-327845
8. Örtqvist, A. K., Lundholm, C., Kieler, H., Ludvigsson, J. F., Fall, T., Ye, W., & Almqvist, C. (2014). Antibiotics in fetal and early life and subsequent childhood asthma: Nationwide population based study with sibling analysis. BMJ, 349, g6979. https://doi.org/10.1136/bmj.g6979
9. Ducarmon, Q. R., Zwittink, R. D., Hornung, B. V. H., van Schaik, W., Young, V. B., & Kuijper, E. J. (2019). Gut microbiota and colonization resistance against bacterial enteric infection. Microbiology and Molecular Biology Reviews, 83(3), e00007-19. https://doi.org/10.1128/MMBR.00007-19
10. Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. The New England Journal of Medicine, 364(1), 22-32. https://doi.org/10.1056/NEJMoa1004409

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 18 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP